title: Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy.
authors.affiliation: Unit of Pharmacoeconomics and Health Technology Assessment, ESTAV Toscana Centro, Regional Health Service, Firenze, Italy. andrea.messori@estav-centro.toscana.it.
authors.forename: A
authors.initials: A
authors.lastname: Messori
authors.forename: D
authors.initials: D
authors.lastname: Maratea
authors.forename: V
authors.initials: V
authors.lastname: Fadda
authors.forename: S
authors.initials: S
authors.lastname: Trippoli
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000069474:Sofosbuvir; D014542:Uridine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D000069474:Sofosbuvir; D014542:Uridine Monophosphate; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase